Keywords: boeh, ing, study, dabigatran, etexilate, acs, german

Boeh Ing to study dabigatran etexilate in ACS

Article | 17 December 2007

German, privately-owned drugmaker Boehringer Ingelheim has announced the initiation of a trial of its novel direct thrombin inhibitor, dabigatran etexilate, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Boehringer Ingelheim

Go to company listing

Related Drugs

Nystatin

Go to drug listing